Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
08/2005
08/04/2005WO2005070461A2 Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
08/04/2005WO2005070460A2 Combination therapy with 5-ht1a and 5-ht1b receptor antagonists
08/04/2005WO2005070459A1 Method of continuing expression of vector repeatedly administered
08/04/2005WO2005070439A1 Implant comprising a human muscle tissue matrix
08/04/2005WO2005070434A2 Treatment of aromatase inhibitor therapy-related osteoporosis
08/04/2005WO2005070427A1 Compounds for the sustained reduction of body weight
08/04/2005WO2005070418A1 Immunomodulatory alkaloids
08/04/2005WO2005070415A1 Adjuvant compositions
08/04/2005WO2005070406A1 Combination of organic compounds
08/04/2005WO2005070328A1 Muscle-based grafts/implants
08/04/2005WO2005070081A2 Methods of using zonisamide as an adjunctive therapy for partial seizures
08/04/2005WO2005070080A2 Methods of using zonisamide as an adjunctive therapy for partial seizures
08/04/2005WO2005070072A2 Reciprocal regulation of inflammation and lipid metabolism by liver x receptors
08/04/2005WO2005070026A2 Drug immunoconjugate combination therapy
08/04/2005WO2005070008A2 Polymer no donor predrug nanofiber coating for medical devices and therapy
08/04/2005WO2005069771A2 Small molecule antagonists of bcl-2 family proteins
08/04/2005WO2005060978A3 Polymetaphosphate based formulations for therapy of microcrystalline arthropathies
08/04/2005WO2005053605A3 Therapeutic liposomes
08/04/2005WO2005042022A3 Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist
08/04/2005WO2005037259A3 Methods and compositions for the prevention or treatment of neoplasia comprising a cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
08/04/2005WO2005034929A3 Tissue remodeling and vascularization
08/04/2005WO2004108072A3 Delivery of immune response modifier compounds using metal-containing particulate support materials
08/04/2005WO2004089283A3 Compositions and methods for treating viral infections
08/04/2005WO2004046309A3 Methods for inhibiting viral replication in vivo
08/04/2005WO2004016726A9 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
08/04/2005WO2004004658A3 Methods and compositions relating to isoleucine boroproline compounds
08/04/2005US20050172352 Using presence of allelic mutation in protein kinase c gene as diagnostic indication of heart disease
08/04/2005US20050171347 Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
08/04/2005US20050171338 Mammalian tribbles signaling pathways and methods and reagents related thereto
08/04/2005US20050171204 2S)-3-(4-{2-[(Cyclohexylmethyl)(heptyl)amino]-2-oxoethoxy}phenyl)-2-ethoxypropanoic acid; treating lipid disorders (dyslipidemias), insulin resistance
08/04/2005US20050171183 Indole-type inhibitors of p38 kinase
08/04/2005US20050171182 inhibitor of the mutant receptor tyrosine kinase and an MEK inhibitor; kits
08/04/2005US20050171177 Method of treatment of Candida isolates
08/04/2005US20050171176 Pharmaceutically active aromatic guanylhydrazones
08/04/2005US20050171151 Administering retinoic acid receptors (RAR) antagonist or an RAR inverse agonist for therapy of hyperlipidemia in mammal
08/04/2005US20050171136 Modulators of the glucocorticoid receptor and method
08/04/2005US20050171129 Polycyclic guanine derivative phosphodiesterase V inhibitors
08/04/2005US20050171122 Mitotic kinesin inhibitors
08/04/2005US20050171116 Vitamin E combined with one or more microbiocides selected from rifampicin, isoniazid, pyrazinamide and ethambutol, complexed with a reducing sugar; improved broad spectrum microbiocidal activity against drug resistant strains of mycobacterium, pseudomonas, escherichia, and staphylococcus
08/04/2005US20050171113 Product comprising an inhibitor of the transduction of heterotrimeric G protein signals combined with an anti-hypertensive agent for therapeutic use in the treatment of arterial hypertension
08/04/2005US20050171098 MCH antagonists and their use in the treatment of obesity
08/04/2005US20050171096 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
08/04/2005US20050171095 Combination of CRF antagonists and 5-HT1B receptor antagonists
08/04/2005US20050171084 Methods of treatment with lxr modulators
08/04/2005US20050171077 Compositions containing piperacillin and tazobactam
08/04/2005US20050171073 An antiestrogen with an antiandrogen; Toremifene with Cyproterone; a SERM and a SARM; Prostate intraepithelial neoplasia, high-grade prostate intraepithelial neoplasia,benign prostate hyperplasia;
08/04/2005US20050171072 Therapeutic combinations and methods including IRM compounds
08/04/2005US20050171070 Stable salts of o-acetylsalicylic acid containing basic amino acids II
08/04/2005US20050171069 Methods and reagents for the treatment of multiple sclerosis
08/04/2005US20050171066 Vivo use of glutathione s-transferase activated nitric oxide donors
08/04/2005US20050171060 Anticancer agents and drug delivery agents with nucleotides
08/04/2005US20050171053 Producing zinc salt antimicrobial agents; precipitating lambda form in alcohol, soaking in metal salt, alcohol and water; separating complex, washing and drying
08/04/2005US20050171050 Composition of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; heart can be better protected during arrest and recovery by using the potassium channel opener adenosine and the local anaesthetic lignocaine
08/04/2005US20050171047 Immunostimulatory nucleic acid molecules
08/04/2005US20050171038 N-allyl-3-{2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide with HIV enzyme inhibitor
08/04/2005US20050171037 Therapeutic combinations
08/04/2005US20050171036 antitumor and anticarcinogenic agent; topoisomerase I inhibitor; synergistic effect by targeting different types of enzymes; low toxicity
08/04/2005US20050171032 Methods for the treatment of cancer
08/04/2005US20050171031 Method and composition for the treatment of cancer
08/04/2005US20050171030 Relieving symptoms of erectile dysfunction and attaining sexual wellness and health of the sexual vascular system with proanthocyanidins
08/04/2005US20050171024 Modulating angiogenesis
08/04/2005US20050171019 Administering an exendin modified with a polymer such as polyethylene glycol, gelatin and/or albumin to increase its biological half-life; treating hyperglucagonemia and diabetes, especially type II diabetes
08/04/2005US20050171009 by addition of surfactants such as nonionic surfactants of the (poly)ethoxylated fatty acid type; storage stability to hydrophobic aggregation nuclei for several months under temperature stress
08/04/2005US20050171007 Therapeutic method
08/04/2005US20050171001 Hemostatic compositions and devices
08/04/2005US20050170440 Treatment and diagnosis of insulin-resistant states
08/04/2005US20050170408 Recombinant g protein coupled receptor for use in identifying modulators for prevention and treatment of cell proliferative disorders
08/04/2005US20050170344 Chds as modifiers of the p53 pathway and methods of use
08/04/2005US20050170015 thiocolchicine and an antiproliferative agent selected from paclitaxel, vinblastine, etoposide, camptothecin, cisplatin, amonafide; causing alkylation damage of DNA or affects topoisomerases or tubulin; anticarcinogenic agent
08/04/2005US20050170013 disodium EDTA; sodium lauryl sulfate; sodium citrate; zinc chloride; and hydrogen peroxide as an oxidant blocks the inflammation chemical and biochemical pathway that leads to a dermatological inflammatory tissue reaction associated with insect bites, burns, diaper rash, jock itch, and other irritants
08/04/2005US20050169996 Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
08/04/2005US20050169988 High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
08/04/2005US20050169967 Surgical material comprising water glass fibres
08/04/2005US20050169966 Growth promoting pharmaceutical implant
08/04/2005US20050169923 monoclonal antibody prevents the growth or differentiation of the B cell; secreted by the hybridoma; therapy of autoimmune diseases, sytematic lupus erythematosus, primary biliary cirrhosis, and idiopathic thrombocytopenic purpura; biodrug
08/04/2005US20050169922 drug screening for compounds that enhance or suppress killer T cell activity by contacting killer T cells which express biliary glycoprotein with a compound that binds biliary glycoprotein and determining the cytotoxicity or proliferation of the killer T cells relative to a control
08/04/2005US20050169920 Pecam-1 modulation
08/04/2005US20050169918 selectively targeting; screening an effect of a Chemokine receptor (CCR4) modulating agent; adjusting the adhesion of T cells to endothelial cells; treating inflammatory skin disease; side effect reduction without affecting on other cells
08/04/2005US20050169913 Administering a monoclonal antibody or enzyme inhibitor of prothrombinase; therapeutic treatment of bacterial and viral infections, allograft and xenograft rejection, cancer, glomerulonephritis, gastrointestinal disorders and fetal loss; inhibiting gene expression of prothrombinase
08/04/2005US20050169902 Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers
08/04/2005US20050169901 controlling cytokine levels by administering extract or secreted products from microorganism; biosynthesis; atheroma, degenerative vascular disease or cardiovascular disease associated with inflammation of the coronary arteries; hypotensive agents, antilipemic agents, anticholesterol agents
08/04/2005US20050169895 Inhibiting proliferation with a matrix of alginate polymers and Strontium coated onto a medical, implantable device: a stent, a cardiac pacemaker, a catheter, a implantable prosthetic, a surgical screw, a surgical wire, a tissue bulking implant
08/04/2005US20050169894 Compositions and methods for ex vivo preservation of blood vessels for vascular grafts using inhibitors of Type III and/or Type IV phosphodiesterases
08/04/2005US20050169889 Immunogenic agent therapy using plasmapheresis or exchange transfusion
08/04/2005US20050169884 Administering an hematopoietic colony stimulating factors of sargramostim; Crohn's Disease
08/04/2005US20050169881 O(chloracetyl-carbamoyl) fumagillol -470 conjugated to hydroxypropyl(meth)acrylamide-methacrylic acid copolymer results in a water soluble composition, lowers the neurotoxicity of TNP-470, avoids penetration of TNP-470 to the cerebrospinal fluid
08/04/2005US20050169848 useful for enhancing immune response to antigens; vaccines; applicable to mucosal immunization in humans
08/04/2005DE102004011392A1 Schwache bis mittelstarke Opioide oder Kombinationen dieser Opioide mit Antidepressiva für die Behandlung von Depressionen, Angststörungen und Schmerzen Mild to moderately potent opioids or combinations of these opioids with antidepressants for the treatment of depression, anxiety disorders and pain
08/04/2005DE102004002557A1 Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen Use of substituted pyrimido (5,4-d) pyrimidines for the treatment of respiratory diseases
08/04/2005CA2595573A1 Methods of treating mesothelioma using an antisense oligonucleotide to thymidylate synthase
08/04/2005CA2593571A1 Methods and compositions for facilitating metabolic control
08/04/2005CA2554333A1 Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
08/04/2005CA2554332A1 Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events
08/04/2005CA2553986A1 Adjuvant compositions
08/04/2005CA2553854A1 Immunomodulatory alkaloids
08/04/2005CA2553649A1 Compounds for the sustained reduction of body weight
08/04/2005CA2553541A1 Chimpanzee adenovirus vaccine carriers
08/04/2005CA2553207A1 Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
08/04/2005CA2552759A1 Combination of organic compounds
08/04/2005CA2552725A1 Treatment of aromatase inhibitor therapy-related osteoporosis
1 ... 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 ... 1151